Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy

被引:18
|
作者
Buijs, P. R. A. [1 ]
van Amerongen, G. [2 ]
van Nieuwkoop, S. [3 ]
Bestebroer, T. M. [3 ]
van Run, P. R. W. A. [3 ]
Kuiken, T. [3 ]
Fouchier, R. A. M. [3 ]
van Eijck, C. H. J. [1 ]
van den Hoogen, B. G. [3 ]
机构
[1] Erasmus MC, Dept Surg, Rotterdam, Netherlands
[2] Viroclin Biosci BV, Rotterdam, Netherlands
[3] Erasmus MC, Dept Virosci, NL-3015 CE Rotterdam, Netherlands
关键词
RESPIRATORY-TRACT; INFLUENZA-VIRUS; VECTORED VACCINE; FUSION PROTEIN; IMMUNIZATION; ANTIBODIES; PV701; CONJUNCTIVITIS; INFECTION; MTH-68/H;
D O I
10.1038/cgt.2014.51
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Newcastle disease virus (NDV) is an avian pararnyxovirus with oncolytic potential. Detailed preclinical information regarding the safety of Oncolytic NDV is scarce. In this study, we evaluated the toxicity, biodistribution and shedding of intravenously injected oncolytic NDVs in non-human primates (Macaca fascicularis). Two animals were injected with escalating doses of a non-recombinant Vaccine strain, a recombinant lentogenic strain or a recombinant mesogenic strain. To study transmission, naive animals: were co-housed with the injected animals. Injection with NDV did not lead to severe illness in the animals or abnormalities in hematologic or biochemistry Measurements. Injected animals shed low amounts of virus, but this did not lead to seroconversion of the contact animals. Postmortem evaluation demonstrated no pathological changes or evidence of virus replication. This study demonstrates that NDV generated in embryonated chicken eggs is safe for intravenous administration to non-human primates. In addition, our study Confirmed results from a previous report that naive primate and human sera are able to neutralize egg-generated NDV. We discuss the implications of these results for our study and the Use of NDV for virotherapy.
引用
收藏
页码:463 / 471
页数:9
相关论文
共 44 条
  • [1] Construction of Recombinant Newcastle Disease Virus Italien Strain for Oncolytic Virotherapy of Tumors
    Wei, Ding
    Sun, Na
    Nan, Gang
    Wang, Yuan
    Liu, Hong-Qi
    Peeters, Ben
    Chen, Zhi-Nan
    Bian, Huijie
    HUMAN GENE THERAPY, 2012, 23 (07) : 700 - 710
  • [2] Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response
    DiNapoli, Joshua M.
    Yang, Lijuan
    Samal, Siba K.
    Murphy, Brian R.
    Collins, Peter L.
    Bukreyev, Alexander
    VACCINE, 2010, 29 (01) : 17 - 25
  • [3] Use of reverse genetics to enhance the oncolytic properties of newcastle disease virus
    Vigil, Adam
    Park, Man-Seong
    Martinez, Osvaldo
    Chua, Mark A.
    Xiao, Sa
    Cros, Jerome F.
    Martinez-Sobrido, Luis
    Woo, Savio L. C.
    Garcia-Sastre, Adolfo
    CANCER RESEARCH, 2007, 67 (17) : 8285 - 8292
  • [4] Transmission of Ebola virus from pigs to non-human primates
    Weingartl, Hana M.
    Embury-Hyatt, Carissa
    Nfon, Charles
    Leung, Anders
    Smith, Greg
    Kobinger, Gary
    SCIENTIFIC REPORTS, 2012, 2
  • [5] Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo
    Al-Shammari, Ahmed Majeed
    Jalill, Raghad Dhyea Abdul
    Hussein, Mohammed F.
    MOLECULAR BIOLOGY REPORTS, 2020, 47 (03) : 1691 - 1702
  • [6] Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates
    Cassady, Kevin A.
    Bauer, David F.
    Roth, Justin
    Chambers, Melissa R.
    Shoeb, Trent
    Coleman, Jennifer
    Prichard, Mark
    Gillespie, G. Yancey
    Markert, James M.
    MOLECULAR THERAPY-ONCOLYTICS, 2017, 5 : 1 - 10
  • [7] Immune Response to the West Nile Virus in Aged Non-Human Primates
    Wertheimer, Anne M.
    Uhrlaub, Jennifer L.
    Hirsch, Alec
    Medigeshi, Guruprasad
    Sprague, Jerald
    Legasse, Alfred
    Wilk, Jennifer
    Wiley, Clayton A.
    Didier, Peter
    Tesh, Robert B.
    Murray, Kristy O.
    Axthelm, Michael K.
    Wong, Scott W.
    Nikolich-Zugich, Janko
    PLOS ONE, 2010, 5 (12):
  • [8] Characterization of a 2016 Clinical Isolate of Zika Virus in Non-human Primates
    Li, Xiao-Feng
    Dong, Hao-Long
    Huang, Xing-Yao
    Qiu, Ye-Feng
    Wang, Hong-Jiang
    Deng, Yong-Qiang
    Zhang, Na-Na
    Ye, Qing
    Zhao, Hui
    Liu, Zhong-Yu
    Fan, Hang
    An, Xiao-Ping
    Sun, Shi-Hui
    Gao, Bo
    Fa, Yun-Zhi
    Tong, Yi-Gang
    Zhang, Fu-Chun
    Gao, George F.
    Cao, Wu-Chun
    Shi, Pei-Yong
    Qin, Cheng-Feng
    EBIOMEDICINE, 2016, 12 : 170 - 177
  • [9] A Recombinant Subunit Based Zika Virus Vaccine Is Efficacious in Non-human Primates
    Medina, Liana O.
    To, Albert
    Lieberman, Michael M.
    Wong, Teri Ann S.
    Namekar, Madhuri
    Nakano, Eileen
    Andersen, Hanne
    Yalley-Ogunro, Jake
    Greenhouse, Jack
    Higgs, Stephen
    Huang, Yan-Jang S.
    Vanlandingham, Dana L.
    Horton, Jaime S.
    Clements, David E.
    Lehrer, Axel T.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [10] Serological Detection of Ebola Virus Exposures in Native Non-human Primates of Southern Nigeria
    Ogunro, B. N.
    Olugasa, B. O.
    Verschoor, E. J.
    Olarimoye, A. O.
    Theyse, I
    Niphuis, H.
    JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2018, 8 (3-4) : 162 - 170